Regeneron Pharmaceuticals, Inc.(REGN)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
REGN | 85.31 B | 20.87x | 16.70% | 27.87% | $40.42 | 14.04% | 8.54 | 47.00% | $847.00 | $538.24 |
FOLD | - | - | - | - | - | - | - | - | - | - |
VRTX | 141.42 B | 32.33x | 12.50% | 35.00% | $17.26 | 23.54% | 9.77 | - | $555.69 | $374.17 |
ALNY | 35.39 B | 45.45x | 66.90% | 16.13% | $5.82 | 96.56% | 2.21 | - | $495.55 | $197.81 |
CRSP | 5.46 B | -12.15x | 10.41% | - | $-4.65 | -26.10% | 0.45 | - | $78.48 | $44.12 |
RXRX | 1.84 B | -3.44x | -60.10% | - | $-1.00 | -56.58% | 7.28 | - | $7.18 | $2.77 |
Peer Valuation & Performance Analysis
Peer group analysis for Regeneron Pharmaceuticals, Inc. (REGN) compared to its primary competitors (including FOLD, VRTX, ALNY) reveals distinct metrics. REGN trades at a valuation premium compared to its competitors, with a P/E ratio of 20.9x versus the peer average of 11.7x (representing a 79% premium). This indicates that the market expects superior growth or commands a quality premium for REGN. In terms of growth, REGN's revenue growth of 16.7% exceeds the peer average of -3.3%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 27.9% compared to the peer average of 25.6%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• REGN ranks #1 in P/E ratio, #2 in revenue growth, and #2 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $858.19 | $859.34 | $837.63 | $843.47 | 496,200 | -1.72% |
| 2026-09-02 | $826.24 | $854.49 | $825.77 | $852.03 | 749,400 | +3.12% |
| 2026-09-01 | $808.86 | $824.63 | $804.32 | $823.82 | 682,600 | +1.85% |
| 2026-08-31 | $782.44 | $802.78 | $779.08 | $799.08 | 894,100 | +2.13% |
| 2026-08-28 | $809.40 | $809.40 | $789.08 | $794.19 | 487,700 | -1.88% |
| 2026-08-27 | $806.18 | $817.62 | $804.27 | $807.71 | 766,800 | +0.19% |
| 2026-08-26 | $827.78 | $831.67 | $814.70 | $814.79 | 585,300 | -1.57% |
| 2026-08-25 | $829.22 | $839.94 | $823.44 | $833.56 | 505,400 | +0.52% |
| 2026-08-24 | $834.51 | $834.70 | $823.40 | $828.50 | 672,000 | -0.72% |
| 2026-08-21 | $835.74 | $847.00 | $826.64 | $834.04 | 786,800 | -0.20% |
| 2026-08-20 | $831.70 | $840.82 | $826.05 | $826.64 | 596,400 | -0.61% |
| 2026-08-19 | $817.17 | $844.92 | $815.38 | $840.84 | 750,400 | +2.90% |
| 2026-08-18 | $814.00 | $821.02 | $805.93 | $810.24 | 779,000 | -0.46% |
| 2026-08-17 | $800.82 | $812.23 | $794.80 | $804.99 | 541,300 | +0.52% |
| 2026-08-14 | $802.35 | $806.54 | $792.57 | $803.48 | 425,600 | +0.14% |
Explore More Analysis for REGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.